L'Oreal U.S. settles first hair relaxer cancer trial cases in Chicago

L'Oreal U.S. settles first hair relaxer cancer trial cases in Chicago
L'Oreal settles cancer claims

A first set of hair relaxer cancer claims against L'Oreal's U.S. subsidiary and other product makers is resolved during trial proceedings in Chicago. The settlement covers four women and comes as thousands of similar lawsuits over chemical hair straighteners continue in state and federal courts.

Highlights

  • L'Oreal's U.S. subsidiary and other companies reached a confidential settlement with four plaintiffs during the first Chicago trial over hair relaxer-related cancer claims.
  • Over 12,700 similar cases remain centralized before a federal judge in Chicago, with additional lawsuits filed at the state level against L'Oreal and others.
  • A 2022 National Institutes of Health study reported that frequent use of chemical hair straighteners more than doubles uterine cancer risk, prompting expanded litigation and state-level suits in Arizona and Minnesota.

Settlement during first Chicago trial

As reported by Reuters, the four plaintiffs reach a confidential settlement on Monday with L'Oreal's U.S. subsidiary and other companies during what lawyers say is the first trial over claims that chemical hair straightening products caused gynecologic cancers.

The women, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, sued in Cook County, Illinois, in 2023 and 2024. Jury selection in the case begins on November 9, and attorney Danielle Ward Mason says in a statement that she hopes the agreement gives the women a sense of justice.

L'Oreal says its highest priority is the health and wellbeing of consumers and that it remains confident in the safety of its SoftSheen-Carson hair products, including hair relaxers. The company also says it follows regulations in every market where it operates and subjects its products to rigorous scientific safety evaluation.

Broader litigation and industry pressure

Thousands of similar claims are still moving through the courts. More than 12,700 cases are centralized before a federal judge in Chicago, while other lawsuits have also been filed in state court, according to court records.

The products at issue, sold under names including Dark and Lovely and Optimum, promise to permanently straighten textured hair and have been widely marketed to Black women. Litigation expands after a 2022 National Institutes of Health study finds that women who use the products several times a year are more than twice as likely to develop uterine cancer.

L'Oreal says that study does not establish a causal link between use of the products and the conditions alleged by plaintiffs. Arizona and Minnesota also sue L'Oreal this year, alleging the company misleads women about the products' safety.

We recently reported on the Visa Mastercard settlement as the card networks sought court approval for a $38 billion deal with U.S. merchants.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.